美国Sanford Burnham Prebys医学研究所Jorge Moscat课题组对非典型蛋白激酶C（aPKC）在肿瘤中的双重作用进行了总结性评述。2019年8月29日，《癌细胞》在线发表了这一文章。

非典型蛋白激酶C（aPKC）同工酶PKCλ/ι和PKCζ现在被认为是肿瘤发生的基本调节者。然而，决定其在癌症中不同作用功能的具体差别之处仍然有待研究。两种aPKC都具有多种背景依赖性功能，可以转化为肿瘤起始或抑制功能。研究人员回顾早期和最近的文献，讨论了不同的肿瘤类型及其微环境如何解释每个aPKC同种型的选择性信号。这些内容与临床相关，因为更好地理解这些激酶的作用，对于新型抗癌疗法的研发是必不可少的。

附：英文原文

Title: The Dual Roles of the Atypical Protein Kinase Cs in Cancer

Author: Miguel Reina-Campos, Maria T. Diaz-Meco, Jorge Moscat

Issue&Volume: 29 August 2019

Abstract: Atypical protein kinase C (aPKC) isozymes, PKCλ/ι and PKCζ, are now considered fundamental regulators of tumorigenesis. However, the specific separation of functions that determine their different roles in cancer is still being unraveled. Both aPKCs have pleiotropic context-dependent functions that can translate into tumor-promoter or -suppressive functions. Here, we review early and more recent literature to discuss how the different tumor types, and their microenvironments, might account for the selective signaling of each aPKC isotype. This is of clinical relevance because a better understanding of the roles of these kinases is essential for the design of new anti-cancer treatments.

DOI: https://doi.org/10.1016/j.ccell.2019.07.010

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30337-X#